Incorrect password
evipedia.ai Suggest Edit

Thiamine for Health & Longevity

Evidence Review created on 04/25/2026 using AI4L / Opus 4.7

Also known as: Vitamin B1, Thiamin, Aneurin, Benfotiamine, Sulbutiamine, Thiamine HCl, Thiamine Mononitrate

Motivation

Thiamine (vitamin B1) is a water-soluble B vitamin that serves as a cofactor for enzymes central to cellular energy production. It was the first vitamin to be chemically isolated, and its deficiency disease, beriberi, helped launch modern nutrition science. Longevity-oriented interest in thiamine has grown because subtle, undetected shortfalls appear more common than overt deficiency, especially among older adults, individuals on diuretics or metformin, those with high alcohol intake, and people after bariatric surgery.

Synthetic derivatives such as benfotiamine, a fat-soluble form developed in Japan in the 1950s, and sulbutiamine, achieve substantially higher tissue levels than ordinary thiamine salts. Recent clinical work has prompted investigation of whether these higher-bioavailability forms can support cognitive aging, glucose handling, and vascular health beyond simple deficiency correction.

This review examines what is and is not established for thiamine and its main derivatives, where the evidence is conflicted or thin, the practical protocols used in clinical and longevity settings, and the relevant interactions, monitoring approaches, and quality considerations.

Benefits - Risks - Protocol - Conclusion

A curated set of accessible, high-quality overviews of thiamine and benfotiamine from clinicians, researchers, and longevity-oriented publications.

  • Benfotiamine’s Effects on Measures of Brain Aging - Walter Regents (published in Life Extension Magazine, the publishing arm of Life Extension, a commercial seller of benfotiamine and B-vitamin products, representing a potential conflict of interest)

    Long-form magazine article unpacking the Phase IIa benfotiamine trial in early Alzheimer’s disease, with a longevity-oriented framing of the underlying mechanism (advanced glycation end-product reduction and improved brain glucose metabolism) and concrete dose ranges used in the study and in general supplementation.

  • Vitamin B1 (Thiamin) - Harvard T.H. Chan School of Public Health

    Academic overview of thiamine’s biochemical functions, dietary sources, intake recommendations, deficiency risk groups, and supplementation considerations, written for an educated lay audience and useful as a balanced baseline reference.

  • Thiamine and benfotiamine: Focus on their therapeutic potential - Bozic et al., 2023

    Detailed narrative review comparing the pharmacokinetics, neuroprotective effects, and therapeutic potential of thiamine versus benfotiamine, with emphasis on benfotiamine’s superior bioavailability and emerging applications in neurodegenerative and metabolic disease.

  • The importance of thiamine (vitamin B1) in humans - Mrowicka et al., 2023

    Comprehensive narrative review covering thiamine’s role as a coenzyme in energy metabolism and neurotransmitter synthesis, its antioxidant properties, the spectrum of deficiency from peripheral neuropathy to Wernicke-Korsakoff syndrome, and the clinical relevance for at-risk populations.

  • Thiamin - Health Professional Fact Sheet - National Institutes of Health Office of Dietary Supplements

    Authoritative clinical reference covering thiamine’s biochemistry, recommended dietary allowances, food sources, absorption, populations at risk for deficiency, and documented interactions with medications such as loop diuretics (a class of high-potency diuretic drugs that act on the loop of Henle in the kidney to increase urine output) and fluorouracil.

Rhonda Patrick (foundmyfitness.com), Peter Attia (peterattiamd.com), Andrew Huberman (hubermanlab.com), and Chris Kresser (chriskresser.com) do not appear to have dedicated standalone overviews of thiamine or benfotiamine; site searches and combined web searches as of 04/25/2026 surfaced only brief contextual mentions within broader nutrition discussions, which did not meet the “high-level overview” threshold for inclusion.

Grokipedia

Thiamine

Encyclopedic overview of thiamine covering its chemistry as a sulfur-containing coenzyme precursor, dietary requirements and food sources, biochemical roles via thiamine pyrophosphate in pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase reactions, deficiency syndromes including beriberi and Wernicke-Korsakoff, and synthetic derivatives such as benfotiamine and sulbutiamine.

Examine

Vitamin B1

Evidence-graded supplement monograph covering thiamine’s role in glucose metabolism and neurotransmitter synthesis, dose ranges typically studied for deficiency states (100-300 mg/day) and for benfotiamine (300-600 mg/day), and structured research breakdowns across heart failure, type 2 diabetes, prediabetes, and premenstrual syndrome.

ConsumerLab

Thiamin (Vitamin B1)

ConsumerLab’s hub page on thiamin gathering product reviews and quality testing notes for B-complex and standalone B1 products, including findings that some tested B-complexes have delivered substantially less than their labeled thiamine content, underscoring the value of third-party verification when selecting products.

Systematic Reviews

The following systematic reviews and meta-analyses examine the most clinically relevant questions for thiamine and benfotiamine supplementation in humans.

Mechanism of Action

Thiamine functions in the body almost entirely through its phosphorylated active form, thiamine pyrophosphate (TPP, also known as thiamine diphosphate, TDP). TPP is an essential cofactor for several enzyme complexes that sit at junctions in carbohydrate, amino acid, and energy metabolism:

  • Pyruvate dehydrogenase complex (PDC): catalyzes the irreversible conversion of pyruvate (the end product of glycolysis) into acetyl-CoA (acetyl-coenzyme A, the entry molecule for the citric acid cycle), linking glucose breakdown to mitochondrial energy production. When thiamine is insufficient, pyruvate accumulates and is shunted to lactate, contributing to metabolic acidosis
  • Alpha-ketoglutarate dehydrogenase complex (KGDHC): a rate-limiting step within the citric acid cycle (also called the Krebs cycle, the central pathway producing the high-energy electron carriers used by mitochondria). Reduced KGDHC activity is one of the earliest measurable metabolic changes in Alzheimer’s disease brain tissue
  • Branched-chain alpha-keto acid dehydrogenase (BCKDH): required for catabolism of the branched-chain amino acids leucine, isoleucine, and valine
  • Transketolase (TKT): the central enzyme of the pentose phosphate pathway, which generates NADPH (nicotinamide adenine dinucleotide phosphate, used for cellular antioxidant defense and biosynthesis) and ribose-5-phosphate for nucleotide and DNA synthesis

Beyond its coenzyme roles, thiamine also participates in the synthesis of acetylcholine (a neurotransmitter important for memory, attention, and parasympathetic function) and supports myelin maintenance and nerve impulse conduction. Independent of its coenzyme function, thiamine has direct antioxidant activity, scavenging reactive oxygen species and inhibiting lipid peroxidation.

Benfotiamine is a fat-soluble S-Acyl thiamine derivative. After ingestion, it is dephosphorylated in the intestine to S-Benzoylthiamine, which crosses cell membranes passively (rather than relying on the saturable SLC19A2 and SLC19A3 thiamine transporters, the two main intestinal and cellular proteins that move thiamine across membranes), then is converted intracellularly to free thiamine and TPP. This non-saturable absorption produces blood thiamine levels approximately five times higher than equimolar thiamine hydrochloride and meaningfully higher tissue thiamine concentrations, particularly in nerve, liver, and kidney; brain accumulation is more modest. Sulbutiamine, another lipid-soluble derivative, more readily crosses the blood-brain barrier and has been used primarily for fatigue and cognitive indications.

Competing mechanistic interpretations exist for benfotiamine’s claimed metabolic benefits. The “transketolase activation” hypothesis posits that higher tissue TPP shunts excess glucose intermediates away from harmful glycation (the spontaneous attachment of sugars to proteins) and polyol pathways (an alternative glucose-handling route that consumes NADPH and contributes to oxidative stress in diabetes), lowering AGEs (advanced glycation end-products, harmful protein-sugar adducts). Critics note that some preclinical work attributes part of benfotiamine’s anti-AGE signal to direct effects of S-Benzoylthiamine itself rather than transketolase activation, which would make the dose-response relationship less straightforward than initially assumed.

Pharmacological properties (thiamine hydrochloride):

  • Half-life: plasma half-life roughly 1-5 hours depending on dose; tissue half-life of stored thiamine approximately 9-18 days
  • Selectivity: acts as a coenzyme for specific TPP-dependent enzymes; no receptor binding
  • Tissue distribution: body stores roughly 25-30 mg total, concentrated in skeletal muscle, heart, liver, kidneys, and brain
  • Metabolism: absorbed actively in the small intestine via SLC19A2 and SLC19A3; phosphorylated intracellularly by thiamine pyrophosphokinase to TPP; not metabolized by cytochrome P450 enzymes; excess and metabolites excreted renally

Historical Context & Evolution

Thiamine’s history is inseparable from beriberi, an often-fatal disease that ravaged populations consuming polished white rice across East and Southeast Asia from the late 19th century onward. In the 1880s, the Japanese naval physician Takaki Kanehiro showed that beriberi in sailors could be largely eliminated by replacing white rice with mixed rations including barley, meat, and vegetables. Soon after, the Dutch physician Christiaan Eijkman observed that chickens fed polished rice developed a beriberi-like polyneuritis (inflammation of multiple peripheral nerves) that could be cured by switching to unpolished rice; this work, with later contributions by Gerrit Grijns, helped establish the concept of a deficiency disease and earned Eijkman a share of the 1929 Nobel Prize in Physiology or Medicine.

In 1926, Barend Jansen and Willem Donath isolated the active anti-beriberi factor from rice bran. In 1936, Robert R. Williams determined its chemical structure and synthesized it, naming it “thiamine” from “thio” (sulfur) and “amine” (the amino group), launching the era of vitamin chemistry. Thiamine was initially used purely as a deficiency treatment, including in fortification programs that effectively eliminated overt beriberi in many countries.

From the mid-20th century onward, two parallel developments expanded interest beyond deficiency. First, researchers identified subclinical thiamine insufficiency as common in older adults, in patients on long-term loop diuretics, in heart failure, in alcohol use disorder, and after bariatric surgery, prompting questions about whether modest supplementation might benefit groups not classically considered “deficient”. Second, in postwar Japan, fat-soluble allithiamine derivatives were developed from garlic, leading to benfotiamine and other lipid-soluble forms designed to overcome the saturable absorption limit of ordinary thiamine salts. Benfotiamine was approved in Germany as a prescription medicine for diabetic neuropathy and is sold over the counter as a supplement in the United States.

Modern interest in benfotiamine for healthy aging and cognition was catalyzed by the 2020 Phase IIa trial led by Gary E. Gibson and colleagues at the Burke Neurological Institute (a research center that has long pursued benfotiamine’s translational development and is the academic sponsor of the follow-up BenfoTeam program, representing a potential conflict of interest), which suggested that 600 mg/day benfotiamine slowed cognitive decline in early Alzheimer’s disease. The original research findings, the magnitude of effect, and the mechanistic plausibility have been described and analyzed in multiple subsequent reviews, but a single small trial is not yet definitive evidence; replication studies, including the larger BenfoTeam Phase 2 trial, are underway.

Expected Benefits

A dedicated search of NIH ODS, Examine, Life Extension, drugs.com, and PubMed for the full benefit profile of thiamine and benfotiamine was performed before writing this section.

High 🟩 🟩 🟩

Correction of Frank Thiamine Deficiency

Thiamine reliably and rapidly reverses overt deficiency syndromes including dry and wet beriberi (peripheral neuropathy, high-output cardiac failure, edema) and Wernicke-Korsakoff syndrome (acute confusion, ophthalmoplegia (paralysis of the eye muscles), ataxia (loss of muscle coordination), and chronic memory impairment). Intravenous administration is standard for acute Wernicke’s encephalopathy because of the speed and reliability of response. The systematic review by Cantu-Weinstein et al. (2024) reported partial or complete symptom resolution in roughly 90% of Wernicke’s encephalopathy cases.

Magnitude: Symptom resolution in approximately 90% of Wernicke’s encephalopathy cases treated with adequate IV (intravenous) thiamine; full reversal of beriberi symptoms within days to weeks of repletion.

Prevention of Subclinical Deficiency in High-Risk Groups

Routine supplementation prevents the slow neurological and cardiovascular consequences of chronic thiamine depletion in groups at elevated risk: chronic loop diuretic users, post-bariatric surgery patients, individuals with alcohol use disorder, those with chronic gastrointestinal disease, and older adults with poor nutrition. Jain et al. (2015) found thiamine deficiency was 2.5-fold more prevalent in heart failure patients than in controls (OR 2.53). Post-bariatric surgery deficiency rates have been reported around 27% in observational cohorts.

Magnitude: OR 2.53 for thiamine deficiency in heart failure versus controls; approximately 27% prevalence after bariatric surgery in published cohorts.

Medium 🟩 🟩

Lipid Profile Improvement in Type 2 Diabetes

Meta-analytic evidence indicates thiamine and benfotiamine modestly improve lipid parameters in people with type 2 diabetes. Muley et al. (2022) found thiamine supplementation significantly increased HDL cholesterol, while benfotiamine at 120 mg/day significantly reduced triglycerides; HbA1c and fasting glucose were not significantly changed. The effect is modest but reproducible across pooled trials.

Magnitude: HDL increase mean difference (MD) 0.10 mmol/L (95% CI 0.10-0.20); triglyceride decrease MD -1.10 mmol/L (95% CI -1.90 to -0.30) with benfotiamine 120 mg/day in pooled diabetic cohorts.

Reduction of Advanced Glycation End-Products

Benfotiamine at supraphysiological doses can lower circulating AGEs and inhibit AGE-driven downstream signaling, mechanisms relevant to vascular aging, retinopathy, and neurodegeneration. The Gibson et al. Phase IIa Alzheimer’s trial reported a significant fall in serum AGEs at 12 months. Whether this surrogate endpoint translates into hard clinical outcomes remains open.

Magnitude: Significant reduction (p = 0.044) in blood AGE levels at 12 months with 600 mg/day benfotiamine in early Alzheimer’s disease.

Low 🟩

Slowing of Cognitive Decline in Early Alzheimer’s Disease ⚠️ Conflicted

In a single Phase IIa randomized, double-blind, placebo-controlled trial in 70 participants with mild cognitive impairment or early Alzheimer’s disease, 600 mg/day benfotiamine for 12 months reduced worsening on the CDR (Clinical Dementia Rating, a global dementia severity scale) by 77% (p = 0.034) versus placebo, with effects more pronounced in APOE4 (apolipoprotein E ε4 allele, a genetic variant that increases Alzheimer’s risk) non-carriers. ADAS-Cog (Alzheimer’s Disease Assessment Scale-Cognitive Subscale) showed 43% less worsening, but this did not reach statistical significance. Confirmatory replication is pending in the larger BenfoTeam trial; until then, this remains an unconfirmed signal from a single small trial.

Magnitude: 77% reduction in CDR worsening; 43% non-significant reduction in ADAS-Cog worsening over 12 months in early Alzheimer’s disease.

Reduction of ICU Delirium

Pooled RCT data in critically ill patients suggest thiamine supplementation reduces the incidence of ICU (intensive care unit) delirium relative to placebo. The reported odds reduction is meaningful, though available trials are small and heterogeneous, and a corresponding mortality benefit has not been demonstrated.

Magnitude: Not quantified in available studies.

Symptomatic Relief in Diabetic Peripheral Neuropathy

Several small RCTs of benfotiamine, often combined with vitamins B6 and B12, report improvements in pain, paresthesia (abnormal tingling, prickling, or burning sensations), and vibration perception thresholds in diabetic peripheral neuropathy. Effect sizes are modest, control conditions vary, and not all trials have shown benefit; the German regulatory approval of benfotiamine for this indication reflects the cumulative signal more than any single definitive trial.

Magnitude: Statistically significant improvement in neuropathy symptom scores in trials using 300-600 mg/day benfotiamine for 6-12 weeks; specific effect sizes vary by trial and outcome scale.

Speculative 🟨

Cortisol and Stress Response Modulation

Small studies have suggested that perioperative intramuscular thiamine attenuates the cortisol surge associated with surgical stress. The mechanism is presumed to involve support of mitochondrial energy production under acute stress. Evidence is limited to small studies and has not been replicated in larger trials.

Migraine Prevention

A cross-sectional analysis using NHANES (National Health and Nutrition Examination Survey, a U.S. population health database) found that higher dietary thiamine intake was associated with lower odds of severe migraine or headache in women but not men. No interventional trial has tested thiamine supplementation specifically for migraine prevention.

Chronic Fatigue Reduction in Inflammatory Bowel Disease

Open-label work and small case series have reported improvement in chronic fatigue at very high oral thiamine doses (600-1500 mg/day) in patients with inflammatory bowel disease (chronic intestinal inflammatory conditions including Crohn’s disease and ulcerative colitis). The mechanism is unclear, and controlled trials are needed before drawing firm conclusions.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in SLC19A2 (encoding the thiamine transporter THTR1) and SLC19A3 (encoding THTR2, both intestinal and cellular thiamine transporters) can impair absorption and tissue uptake. Loss-of-function SLC19A2 mutations cause thiamine-responsive megaloblastic anemia syndrome. Selected SLC19A3 variants are associated with severity of metabolic and neurological phenotypes and modulate the response to oral thiamine. APOE4 carriers showed attenuated cognitive benefit from benfotiamine in the Gibson 2020 trial, suggesting genotype-by-treatment interaction for cognitive outcomes
  • Baseline biomarker levels: Individuals with frank or marginal deficiency on whole blood thiamine or transketolase assays show the most pronounced symptomatic benefits; individuals with already-adequate stores typically derive little additional benefit beyond AGE-related and lipid effects in specific disease settings
  • Sex-based differences: Recommended intake differs slightly by sex (1.2 mg/day for adult men, 1.1 mg/day for adult women per U.S. RDAs (Recommended Dietary Allowances, the average daily intake level sufficient to meet the nutrient requirements of nearly all healthy people)), reflecting modest metabolic differences. The migraine signal in NHANES was present in women only. No large trials have specifically powered sex-based subgroup analyses for therapeutic thiamine doses
  • Pre-existing health conditions: Diabetes, heart failure, alcohol use disorder, inflammatory bowel disease, chronic kidney disease, and post-bariatric anatomy all increase thiamine requirements and the likelihood of benefit from supplementation. Conditions characterized by oxidative stress and impaired mitochondrial function are theoretically more responsive
  • Age: Older adults (over 65) are disproportionately likely to have low intake, reduced active intestinal absorption, and concurrent medications (especially loop diuretics) that increase urinary thiamine losses; they therefore tend to derive greater absolute benefit from routine supplementation than younger adults

Potential Risks & Side Effects

A dedicated search of drugs.com, NHS, Mayo Clinic, FDA prescribing information, and NIH ODS for the complete side effect profile of thiamine and benfotiamine was performed before writing this section.

High 🟥 🟥 🟥

Very Low Toxicity with Oral Administration

Thiamine is water-soluble, and excess oral intake is excreted in urine. The U.S. Institute of Medicine has not set a Tolerable Upper Intake Level (UL) due to a lack of evidence for adverse effects from high oral doses in healthy adults. Oral benfotiamine is similarly well tolerated in trials at 300-600 mg/day for up to 12 months.

Magnitude: No established UL; no documented oral toxicity at clinically used doses up to 1500 mg/day in published studies.

Medium 🟥 🟥

Mild Gastrointestinal Discomfort

A minority of users report mild stomach upset, nausea, or loose stools at higher oral doses (typically above 100 mg). Effects are dose-dependent, generally transient, and usually resolve with dose reduction or taking with food.

Magnitude: Uncommon; reported primarily at doses >100 mg/day; typically self-limited.

Low 🟥

Hypersensitivity Reactions to Parenteral Administration

Intravenous and intramuscular thiamine can rarely trigger hypersensitivity reactions, including pruritus (itching), urticaria (hives), angioedema (deep tissue swelling), bronchospasm (sudden constriction of the airways), and very rarely anaphylaxis. The reaction is essentially confined to parenteral administration and is one reason hospitals administer IV thiamine slowly and observe patients afterward.

Magnitude: Reported anaphylaxis incidence approximately 1 per 100,000 IV doses; not relevant to oral supplementation.

Skin Reactions and Odor at High Benfotiamine Doses

Case reports of mild skin rashes and a transient sulfurous body odor (related to thiamine’s sulfur content) have been described at high benfotiamine or thiamine doses. These are uncommon, cosmetic, and reversible on discontinuation.

Magnitude: Rare; described in case reports rather than controlled trials; resolves within days of stopping.

Speculative 🟨

Theoretical B-Vitamin Imbalance at Sustained Very High Doses

Long-term isolated megadosing of any single B vitamin is theoretically capable of perturbing the relative balance of other B vitamins or interfering with certain laboratory assays. No clinical evidence supports this concern at standard supplemental doses, but it is sometimes cited as a rationale for using B-complex products rather than chronic isolated megadoses.

In severely malnourished patients, rapid carbohydrate refeeding before adequate thiamine repletion can precipitate Wernicke’s encephalopathy and refeeding syndrome; here, the risk is from inadequate thiamine, but the speculative concern in the supplementation context is that abrupt reintroduction of high-carbohydrate intake alongside high-dose thiamine could mask early refeeding signs. This is a theoretical concern in specific clinical settings, not a hazard for routine outpatient supplementation.

Risk-Modifying Factors

  • Genetic polymorphisms: SLC19A2 and SLC19A3 variants primarily increase deficiency risk, not toxicity risk. No polymorphisms are known to increase the risk of adverse effects from thiamine supplementation specifically
  • Baseline biomarker levels: Individuals with already-adequate thiamine status simply excrete the excess and rarely experience adverse effects, but they also derive less symptomatic benefit; conversely, severely deficient patients receiving rapid IV repletion alongside glucose can be precipitated into refeeding syndrome and require careful monitoring in clinical settings
  • Sex-based differences: No clinically meaningful sex-based differences in thiamine adverse effects have been documented
  • Pre-existing health conditions: Patients with severe alcohol use disorder, advanced malnutrition, or refeeding scenarios require clinical supervision rather than self-supplementation; individuals with a known prior hypersensitivity to injectable B-complex preparations should avoid parenteral thiamine
  • Age: Older adults can have reduced renal clearance, but given thiamine’s wide safety margin this does not translate into a meaningfully higher adverse-effect rate at usual oral doses

Key Interactions & Contraindications

  • Loop diuretics (furosemide, bumetanide, torsemide): increase urinary thiamine excretion and substantially raise deficiency risk with chronic use. Severity: caution; clinical consequence: subclinical thiamine depletion that can worsen cardiac function. Mitigation: routine 50-100 mg/day oral thiamine and periodic monitoring of whole blood thiamine in chronic loop-diuretic users
  • Metformin: experimental and human data suggest metformin can inhibit the SLC19A3 thiamine transporter, modestly reducing intestinal thiamine absorption. Severity: caution, particularly with high-dose long-term use; clinical consequence: contribution to subclinical deficiency. Mitigation: consider 25-100 mg/day thiamine and assess thiamine status in long-term users
  • Fluorouracil (5-FU, an antimetabolite chemotherapy): can interfere with thiamine utilization and has been associated with rare 5-FU-induced encephalopathy responsive to thiamine. Severity: caution under oncologist supervision; clinical consequence: precipitation of acute thiamine-responsive neurological symptoms. Mitigation: discuss thiamine status proactively with the treating oncology team
  • Phenytoin and other anticonvulsants: chronic use has been associated with decreased thiamine status in some studies. Severity: monitor; clinical consequence: increased deficiency risk over years. Mitigation: routine B-complex supplementation and biomarker monitoring in long-term users
  • Antacids and proton pump inhibitors (PPIs, a class of acid-suppressing drugs; examples: omeprazole, esomeprazole, pantoprazole): prolonged gastric acid suppression can modestly reduce active thiamine absorption. Severity: monitor; clinical consequence: marginally increased deficiency risk. Mitigation: routine modest oral supplementation in long-term PPI users
  • Certain antibiotics (azithromycin, clarithromycin, erythromycin, broad-spectrum agents): can reduce intestinally produced thiamine by altering gut flora. Severity: minor; clinical consequence: small contribution to deficiency in sustained use. Mitigation: temporary supplementation generally sufficient
  • Alcohol: chronic alcohol intake impairs intestinal thiamine absorption, increases urinary losses, and depletes hepatic stores. Severity: major risk factor for clinically significant deficiency; clinical consequence: Wernicke-Korsakoff syndrome. Mitigation: oral or parenteral thiamine in active alcohol use disorder, often via formal medical supervision
  • Magnesium: magnesium is required for thiamine pyrophosphokinase, the enzyme that converts thiamine to its active TPP form. Severity: functional interaction rather than safety concern; clinical consequence: hypomagnesemia can render thiamine supplementation functionally ineffective. Mitigation: assess and correct magnesium status alongside thiamine repletion
  • Other B vitamins (riboflavin, niacin, pyridoxine, folate, B12): thiamine works synergistically with the rest of the B complex in energy metabolism and methylation; isolated very-high-dose B1 supplementation is generally less effective than balanced B-complex repletion in nutritional contexts
  • Other interventions: ketogenic diets and very-low-carbohydrate diets reduce carbohydrate-driven thiamine demand but do not eliminate the need for adequate thiamine intake; conversely, high-carbohydrate refeeding after prolonged starvation requires thiamine pre-loading to avoid refeeding syndrome
  • Populations who should avoid: there are no absolute contraindications to oral thiamine other than documented IgE-mediated thiamine hypersensitivity (extremely rare; reported anaphylaxis incidence approximately 1 per 100,000 IV doses). Parenteral thiamine outside a monitored clinical setting (i.e., without IV access, resuscitation equipment, and trained staff capable of managing Grade 3-4 anaphylaxis within 15 minutes) should be avoided in individuals with any prior Grade ≥2 hypersensitivity reaction to injectable B-complex preparations or any prior anaphylaxis (Ring & Messmer Grade 3-4) to injectable vitamins

Risk Mitigation Strategies

  • Start at standard doses with food: beginning at 25-50 mg/day taken with a meal minimizes the rare GI (gastrointestinal) discomfort that can occur at higher doses, mitigating the gastrointestinal side effects described above
  • Step up benfotiamine gradually: when targeting 300-600 mg/day benfotiamine for cognitive or AGE-lowering goals, escalate over 1-2 weeks (e.g., 150 mg/day for one week, then 300 mg/day, then 600 mg/day if intended), to surface any individual GI sensitivity before reaching the target dose
  • Pair with adequate magnesium: ensure RBC (red blood cell) magnesium is in the optimal range (5.0-6.5 mg/dL) before expecting full thiamine benefit, since magnesium deficiency can render TPP synthesis ineffective; correct hypomagnesemia before drawing conclusions about thiamine response
  • Avoid self-administered IV/IM (intravenous/intramuscular) thiamine: parenteral thiamine should be reserved for clinical settings and supervised use because of the rare anaphylaxis risk and the need for slow administration; this directly mitigates the parenteral hypersensitivity risk
  • Monitor in high-risk pharmacology: individuals on chronic loop diuretics, metformin, phenytoin, or proton pump inhibitors should have whole blood thiamine measured at baseline and roughly annually, with supplementation titrated against status; this mitigates the subclinical deficiency risk arising from drug-induced losses or absorption interference
  • Use B-complex for chronic megadosing: when using sustained doses above 100 mg/day for indications beyond deficiency repletion, including a balanced B-complex (or pairing thiamine with riboflavin, B6, folate, and B12) reduces the theoretical risk of relative B-vitamin imbalance
  • Reassess in pregnancy and lactation: while thiamine requirements rise modestly in pregnancy and lactation (RDAs of 1.4 mg/day), high-dose benfotiamine has not been formally studied in these populations; maintain only RDA-level supplementation unless directed by an obstetric clinician, mitigating uncertainty about high-dose safety in these settings

Therapeutic Protocol

Standard supplementation approaches reflect both nutritional repletion practice and the higher doses used in benfotiamine clinical trials. Two main approaches are seen in practice: a conventional water-soluble thiamine protocol favored by most general practitioners and hospital pharmacists, and a benfotiamine-centered protocol favored by integrative and longevity-oriented clinicians, with no consensus that either is universally superior outside of specific indications.

Standard thiamine maintenance (water-soluble):

  • Dose: 25-100 mg/day of thiamine hydrochloride or thiamine mononitrate; 100 mg/day is a typical “insurance” dose used by Life Extension (a commercial supplement seller whose published dose recommendations align with its own product line, representing a potential conflict of interest) and similar longevity-oriented protocols
  • Timing: taken with a meal, generally in the morning or early afternoon, since thiamine supports energy metabolism and some users perceive a mild stimulating effect
  • Administration: once-daily dosing is sufficient given a tissue half-life of 9-18 days

Benfotiamine protocol (lipid-soluble, higher bioavailability):

  • Dose: 150-300 mg/day for general support; up to 600 mg/day (split into two 300 mg doses) as used in the Gibson 2020 Phase IIa Alzheimer’s trial; 300-600 mg/day in diabetic neuropathy trials
  • Timing: with a fat-containing meal to optimize absorption
  • Administration: doses above 300 mg/day are typically split between morning and evening with meals

Combined approach (Life Extension-style):

  • 100 mg benfotiamine plus 25-50 mg thiamine HCl daily, combining lipid-soluble and water-soluble forms for complementary tissue distribution; popularized by Life Extension Foundation (a commercial supplement seller with a direct financial interest in this protocol)

Half-life considerations: plasma thiamine has a half-life of approximately 1-5 hours depending on dose, while tissue stores have a half-life of 9-18 days. Once-daily dosing maintains steady-state tissue levels; an occasional missed dose is not clinically significant.

Single vs. split dose: for water-soluble thiamine at 25-100 mg/day, once-daily dosing is adequate. For benfotiamine doses at or above 300 mg/day, splitting between morning and evening reduces transient peak-related GI effects and may keep tissue exposure more constant.

Genetic polymorphisms: individuals with SLC19A2 or SLC19A3 variants affecting thiamine transport may benefit from benfotiamine, which bypasses the saturable transporter route. APOE4 carriers considering benfotiamine for cognitive support should know that the Phase IIa trial showed attenuated cognitive benefits in this subgroup. Pharmacogenetically guided dosing remains experimental.

Sex-based differences: there are no established sex-specific dosing adjustments at supplemental doses; the difference in RDA between adult men and women (1.2 vs. 1.1 mg/day) is negligible relative to typical 25-600 mg therapeutic doses.

Age-related considerations: older adults, particularly those over 65 with multiple medications, often start with 50-100 mg/day water-soluble thiamine; those with documented low whole blood thiamine, cognitive concerns, or diabetes may step up to benfotiamine 150-300 mg/day with clinician input. Older adults at the upper end of the target audience age range tend to have higher per-dose absorption efficiency from benfotiamine than from thiamine HCl.

Baseline biomarkers: documented deficiency (whole blood thiamine <70 nmol/L) typically warrants 100-300 mg/day for repletion over several weeks before reverting to maintenance dosing. Elevated lactate or pyruvate in the absence of other causes may also support a repletion trial.

Pre-existing conditions: diabetic patients often prefer benfotiamine for combined absorption and AGE-lowering effects; chronic heart failure patients on loop diuretics commonly take 100 mg/day thiamine HCl as a precaution; individuals with alcohol use disorder require formally supervised parenteral repletion before transitioning to oral maintenance.

Discontinuation & Cycling

  • Long-term vs. short-term: thiamine and benfotiamine are intended for indefinite use as a maintenance nutrient in at-risk populations or as a long-term metabolic support intervention. Short-term high-dose courses (e.g., 600 mg/day benfotiamine for 12 months in the Gibson 2020 trial) have also been used
  • Withdrawal effects: none documented; thiamine does not produce physiological dependence. Individuals who were deficient before supplementation may see deficiency symptoms return on discontinuation if dietary intake remains low
  • Tapering: no taper is required; supplementation can be stopped abruptly without adverse effects
  • Cycling: cycling is not recommended or biologically necessary. Thiamine-dependent enzymes do not develop tolerance, and continuous daily supplementation is the standard approach in both deficiency repletion and longevity-oriented use

Sourcing and Quality

  • Forms: the most common supplemental forms are thiamine hydrochloride and thiamine mononitrate, both water-soluble salts with similar bioavailability. Benfotiamine (S-Benzoylthiamine O-Monophosphate) is the most widely used lipid-soluble derivative, with roughly five-fold higher blood thiamine levels per equimolar dose. Sulbutiamine and fursultiamine are other lipid-soluble derivatives more commonly used in Japan and France, primarily for fatigue and asthenia (generalized weakness or lack of energy) indications
  • Third-party testing: look for products carrying USP Verified, NSF International, or ConsumerLab approval. ConsumerLab testing has historically reported some B-complex products falling well short of label claims for thiamine, supporting the use of independently verified products
  • Reputable brands: longevity-oriented brands include Life Extension (Benfotiamine With Thiamine; Life Extension is a commercial seller of these products, representing a conflict of interest in any of its published recommendations), Pure Encapsulations, Thorne, Doctor’s Best (BenfoMax, with the thiamine derivative branded as such), and NOW Foods. For pharmaceutical-grade benfotiamine, German formulations (e.g., milgamma) are widely cited but require import for U.S. consumers
  • Compounding pharmacies: custom-dosed thiamine HCl and benfotiamine capsules are available through reputable U.S. compounding pharmacies for individuals requiring non-standard doses or excipient-free formulations
  • Quality considerations to look for: label specification of the actual benfotiamine quantity (rather than only “vitamin B1 activity”), clear declaration of the thiamine salt used, absence of unnecessary fillers or artificial colorants, and a reasonable expiration window. Underdosing is a more common quality issue than contamination for thiamine products

Practical Considerations

  • Time to effect: symptomatic deficiency reverses within hours to days for acute Wernicke’s encephalopathy with IV thiamine and over days to weeks for peripheral neuropathy and fatigue with oral repletion. For longevity-oriented use in non-deficient individuals, subjective changes in energy and cognition, if perceptible, typically take 2-4 weeks; the Gibson 2020 trial used a 12-month treatment window for cognitive endpoints
  • Common pitfalls: taking thiamine without adequate magnesium, since hypomagnesemia limits TPP synthesis; assuming a standard multivitamin (typically containing only 1-3 mg) provides a therapeutic dose; choosing benfotiamine but taking it on an empty stomach, which reduces absorption; failing to recognize that loop diuretics, metformin, and chronic alcohol intake actively deplete thiamine; and using sustained isolated megadoses in place of a balanced B-complex when broader B-vitamin support would be more appropriate
  • Regulatory status: thiamine HCl is available over the counter as a dietary supplement and by prescription as an injectable solution. Benfotiamine is sold over the counter in the United States as a dietary supplement and is an approved prescription medicine for diabetic neuropathy in Germany and other countries
  • Cost and accessibility: thiamine HCl is inexpensive (typically USD 5-15 for a 100-count bottle of 100 mg tablets). Benfotiamine costs USD 15-30 for a 120-count bottle of 150-300 mg capsules. Both are widely available through major retailers, online vendors, and pharmacies

Interaction with Foundational Habits

  • Sleep: Thiamine does not directly disrupt sleep; the interaction is generally indirect. Thiamine supports synthesis of acetylcholine and contributes to overall neurotransmitter homeostasis, with limited preliminary evidence that B-complex supplementation including thiamine can modestly improve subjective sleep quality. Practical consideration: morning or early-afternoon dosing is preferred because of the mild perceived energizing effect, rather than because of any direct sedative interaction
  • Nutrition: Thiamine is found in whole grains, legumes, pork, fish, nuts, seeds, and fortified cereals; it is partially destroyed by heat and leached into cooking water. Diets very high in refined carbohydrates and frequent heavy use of tea or coffee (which contain thiamine-degrading factors) can blunt thiamine status; high carbohydrate intake also raises thiamine demand because thiamine is consumed during pyruvate handling. Direction: largely potentiating when paired with a thiamine-rich diet; blunting when paired with a refined-carbohydrate, alcohol-heavy, or thiaminase-rich pattern. Practical consideration: take supplements with a full meal, especially benfotiamine with a fat-containing meal
  • Exercise: Exercise increases mitochondrial energy demand and therefore thiamine turnover. Direction: thiamine supports rather than blunts training adaptations; no evidence of interference with hypertrophy, endurance gains, or recovery. Mechanism: maintained TPP availability for PDC and KGDHC supports oxidative metabolism. Practical consideration: athletes and highly active individuals on calorie-restricted or refined-carbohydrate diets may have modestly elevated thiamine needs; benfotiamine supplementation can raise muscle thiamine more efficiently than equivalent thiamine HCl
  • Stress management: Thiamine appears to support the adrenal stress response; small studies suggest it may attenuate cortisol elevations to acute physiological stress. Direction: indirect, mild buffering of acute stress responses. Mechanism: presumed to involve maintained mitochondrial energetics under stress demand and support of cholinergic and serotonergic pathways. Practical consideration: chronic psychological stress increases B-vitamin utilization in general, and a balanced B-complex including thiamine is often used in stress-management contexts

Monitoring Protocol & Defining Success

Baseline labs are recommended before initiating high-dose thiamine or benfotiamine supplementation, particularly in the presence of risk factors for deficiency (older age, loop diuretics, metformin, alcohol use disorder, prior bariatric surgery, diabetes, or unexplained neuropathy). The following biomarker table covers the most informative tests:

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Thiamine (Whole Blood) 100-200 nmol/L Total body thiamine stores Whole blood preferred over serum; fasting not required. Conventional reference range typically 70-180 nmol/L; functional medicine practitioners often aim for the upper half. RDA = recommended dietary allowance
Thiamine Diphosphate (TDP, Whole Blood) 90-180 nmol/L Most accurate measure of biologically active thiamine Gold-standard assay measured by LC-MS/MS (liquid chromatography-tandem mass spectrometry); preferred in research settings
Erythrocyte Transketolase Activity <15% activation coefficient Functional thiamine status (TPP-dependent enzyme activity) Activation coefficient compares enzyme activity with and without added TPP; values >15-20% indicate functional deficiency
Magnesium (RBC) 5.0-6.5 mg/dL Required cofactor for thiamine pyrophosphokinase that activates thiamine RBC = red blood cell. Conventional range 4.2-6.8 mg/dL. Serum magnesium less reliable than RBC magnesium for tissue stores
Lactate (fasting) 0.5-1.0 mmol/L Elevated lactate may indicate impaired pyruvate dehydrogenase activity from thiamine insufficiency Conventional range 0.5-2.2 mmol/L. Must be drawn without prolonged tourniquet or fist-clenching to avoid false elevation
Homocysteine <8 µmol/L Marker of broader B-vitamin sufficiency (B6, B9, B12 primarily, with thiamine contributing) Conventional range 5-15 µmol/L; useful as a general B-vitamin adequacy check rather than a thiamine-specific test

Ongoing monitoring is recommended at 3 months after initiating therapeutic dosing, then every 6-12 months in stable users; chronic loop diuretic and metformin users benefit from at least annual whole blood thiamine. Cadence summary: baseline, 3 months, then every 6-12 months thereafter (every 6 months for ongoing high-risk pharmacology).

Qualitative markers used to gauge response include:

  • Energy levels and exercise tolerance
  • Cognitive clarity, focus, and memory (for higher-dose benfotiamine in cognitively focused use)
  • Peripheral nerve sensation and absence of paresthesia (for individuals with baseline neuropathy)
  • Frequency and severity of muscle cramps
  • Mood stability and stress tolerance

Emerging Research

  • BenfoTeam Phase 2 Trial: NCT06223360, a multi-site randomized, double-blind, placebo-controlled Phase 2 trial of benfotiamine 600 mg/day in approximately 406 participants with early Alzheimer’s disease across roughly 50 U.S. sites. Designed to confirm or refute the cognitive signal seen in the smaller Gibson 2020 Phase IIa trial, this study could either substantially strengthen or substantially weaken the case for benfotiamine in cognitive aging
  • COLT-HF Trial: NCT05873881, a 2x2 factorial Phase 3 trial testing colchicine and thiamine (300 mg/day) in approximately 2,500 heart failure patients with ischemic heart disease. The largest thiamine trial in heart failure to date, designed to provide definitive data on whether thiamine supplementation provides cardiovascular benefit beyond simple deficiency correction; a null result here would meaningfully weaken the case for routine thiamine in heart failure
  • Diabetic cardiovascular dysfunction: Serra et al., 2025 systematically reviewed seven clinical studies of thiamine in diabetic cardiovascular dysfunction and called for larger multicenter trials with longer follow-up, identifying this as a key direction whose results could strengthen or attenuate the case for thiamine in diabetic cardiovascular care
  • Thiamine, microbiome, and the gut-brain axis: Tao et al., 2025 explores associations between vitamins B1 and B2, gut microbiota composition, and host mental health outcomes including anxiety, stress, and sleep quality; a direction that could broaden or narrow the case for B-vitamin supplementation in mental and longevity contexts
  • SLC19A3 transporter pharmacogenomics: ongoing work in the SLC19A3 thiamine transporter gene (e.g., genetic defects of thiamine transport and metabolism reviewed by Marcé-Grau et al., 2019) could enable personalized dosing strategies, with the potential to either support precision thiamine use or to demonstrate that genotype effects are smaller than hoped
  • Comparative pharmacokinetics of thiamine derivatives: research comparing benfotiamine, sulbutiamine, fursultiamine, and TTFD (thiamine tetrahydrofurfuryl disulfide, a lipid-soluble derivative used as “allithiamine”) for tissue and brain penetration is ongoing and could redirect preferred forms used in clinical and longevity contexts

Conclusion

Thiamine is a foundational B vitamin with an exceptionally favorable safety profile and a well-established role in cellular energy production, nervous system function, and cardiovascular physiology. Its most reliable contribution to longevity-oriented health is preventing and correcting subclinical deficiency, which is more common than generally appreciated in older adults, individuals on loop diuretics or metformin, those with high alcohol intake, and people with diabetes or prior bariatric surgery.

For health-conscious adults, modest daily supplementation with thiamine hydrochloride or with benfotiamine, the lipid-soluble derivative, is supported by a long track record of tolerability and a meaningful biological rationale. Stronger claims for cognitive protection, glycemic control, or cardiovascular benefit beyond deficiency correction rest on a smaller and more conflicted body of evidence, with single trials showing encouraging signals that have not yet been confirmed at scale.

The overall evidence base is mature for deficiency-related uses and still maturing for longevity-oriented applications, with personalized dosing based on thiamine transporter genetics representing an active research frontier. Some of the most-cited cognitive and cardiovascular evidence comes from sources with potential commercial or sponsor interests in benfotiamine and B-vitamin products, a factor relevant to the strength of claims drawn from those sources. Thiamine and its derivatives sit among the lowest-risk, lowest-cost interventions available for closing a real and often hidden gap in metabolic adequacy.

Top - Benefits - Risks - Protocol